Related Experiment Video
Updated: May 10, 2026
MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression
Published on: February 17, 2012
Triple Negative Breast Cancer Heterogeneity and Tumour Microenvironment-based Model Systems' Focus on Druggable
1Department of Bio-medical Sciences, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.
Abstract:
Fifteen to twenty percent of all cases of breast cancer are TNBC (triple negative breast cancer) and exhibit heterogenic features due to their diverse molecular characteristics. Additionally, their aberrant cell cycling behavior contributes to their metastatic capabilities and aggressive nature. TNBC is the only molecular subtype, which lacks the expression of hormone receptors, like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). Hence, it is recalcitrant to hormone therapy. Also, the complex and evolving tumour microenvironment (TME) comprises blood vessels, stromal cells, immune cells, metabolic factors, extracellular matrix (ECM), and an integrated perspective of their interconnections as well as their variability with respect to TNBC progression needs to be comprehended for biomarker/druggable target(s) development and/or their validation. Such TME-based model systems can help us understand the relationship between the different TME components that affect tumour growth and metastasis. This review also catalogs biomarkers and TNBC behaviour within the TME. Also, this review discusses and analyses models that replicate various tumour subtypes that can be correlated with variability in treatment responses, thereby facilitating a better understanding of TNBC heterogeneity. Thus, by identifying biomarkers and constructing model systems, we can augment efforts to overcome treatment failure and poor outcomes in TNBC patients. These subtype-specific TNBC model systems, mirroring the intricacies of the TME, have the potential to provide a feasible and innovative approach to target TNBC cells. This review will facilitate the ongoing global efforts to develop efficacious and safe "tailor-made" drugs for TNBC patients.
Insights
Triple-negative breast cancer (TNBC) is aggressive and lacks hormone receptors, making it hard to treat. Understanding its tumor microenvironment (TME) and developing TNBC models are key to finding new therapies.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers and is characterized by a lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 expression.
- TNBC exhibits aggressive behavior, metastatic potential, and heterogeneity due to diverse molecular characteristics and aberrant cell cycling.
- The tumor microenvironment (TME), comprising various cellular and extracellular components, plays a critical role in TNBC progression and treatment resistance.
Purpose of the Study:
- To review and analyze the complex tumor microenvironment (TME) in triple-negative breast cancer (TNBC).
- To identify biomarkers and druggable targets within the TME for improved TNBC treatment.
- To discuss and evaluate model systems that replicate TNBC subtypes and their variability in treatment responses.
Main Methods:
- Literature review and analysis of existing research on TNBC, its molecular characteristics, and the TME.
- Cataloging of biomarkers associated with TNBC progression and behavior within the TME.
- Discussion and critical analysis of current and emerging TNBC model systems that mimic TME complexity.
Main Results:
- TNBC's heterogeneity and aggressive nature are linked to its molecular profile and the TME.
- The TME significantly influences TNBC growth, metastasis, and therapeutic outcomes.
- Various biomarkers and model systems are being developed to understand and target TNBC.
Conclusions:
- Comprehending the TME is crucial for developing effective biomarkers and therapeutic strategies for TNBC.
- Subtype-specific TNBC model systems that mirror TME intricacies offer innovative approaches for drug development.
- Advancements in understanding TNBC heterogeneity and TME interactions can overcome treatment failures and improve patient outcomes.
